drugset / Trial / NCT06895343

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

NCT06895343

Phase 1 Active not recruiting 100 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

Timeline

Start
2025-04-03
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-701 Unknown Subcutaneous

Indications

No indication recorded.